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DOI 10.1016/j.ccr.2011.11.014SUMMARYHereditary breast cancers are frequently caused by germline BRCA1 mutations. The BRCA1C61G mutation
in the BRCA1 RING domain is a common pathogenic missense variant, which reduces BRCA1/BARD1
heterodimerization and abrogates its ubiquitin ligase activity. To investigate the role of BRCA1 RING
function in tumor suppression and therapy response, we introduced the Brca1C61Gmutation in a conditional
mouse model for BRCA1-associated breast cancer. In contrast to BRCA1-deficient mammary carcinomas,
tumors carrying the Brca1C61G mutation responded poorly to platinum drugs and PARP inhibition and
rapidly developed resistance while retaining the Brca1C61G mutation. These findings point to hypomorphic
activity of the BRCA1-C61G protein that, although unable to prevent tumor development, affects response
to therapy.INTRODUCTION
Hereditary breast and ovarian cancer cases can often be attrib-
uted to germlinemutations in theBRCA1 gene, which confer life-
time risks of up to 90% for developing breast cancer and 40%–
50% for ovarian cancer (Rahman and Stratton, 1998).
The BRCA1 protein has been implicated in maintenance of
genome integrity via processes as DNA replication and repair,
transcriptional regulation and chromatin remodeling (Huen
et al., 2010). Especially its role in error-free repair of DNA
double-strand breaks (DSBs) by homologous recombination
(HR) is thought to be important for its tumor suppression activity
(Moynahan et al., 1999). In the absence of BRCA1, HR isSignificance
Whereas BRCA1-related cancers respond well to therapies ta
tance is a serious clinical problem. Although reversion ofBRCA
it is unclear which functions of BRCA1 are required for therap
BRCA1 proteins with a dysfunctional RING domain triggers a
Genomic instability is viewed as a potential HRD biomarker
different Brca1 mutations have identical genomic profiles, the
therefore be useful to stratify patients according to the unde
loss of RAD51 foci formation.
Canimpaired and DSBs have to be repaired by more error-prone
mechanisms, like nonhomologous end joining, which may lead
to the increased genomic instability that characterizes BRCA1-
mutated tumors (Moynahan et al., 2001).
HR deficiency (HRD) may also underlie the hypersensitivity of
BRCA1-deficient cells to DSB-inducing agents (Bhattacharyya
et al., 2000). Although BRCA1-mutated ovarian cancers are
often sensitive to platinum-based chemotherapy, they may
eventually develop resistance via secondary mutations in the
BRCA1 gene that lead to restoration of function (Swisher et al.,
2008). This finding suggests the existence of a causal link
between BRCA1 status and response to DSB-inducing agents.
BRCA1-deficient cells are also hypersensitive to inhibition ofrgeting homologous recombination deficiency (HRD), resis-
1 germlinemutations has been observed in resistant tumors,
y resistance. Here we show that residual activity of mutant
cquired resistance to PARP inhibitors and platinum drugs.
. However, we show that although mammary tumors with
y respond differently to HRD-targeting therapeutics. It may
rlying BRCA1 mutation and functional biomarkers such as
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BRCA1 RING Function Is Dispensable for Resistancepoly(ADP-ribose) polymerase (PARP) (Bryant et al., 2005; Farmer
et al., 2005), an enzyme involved in DNA single-strand break
(SSB) repair. In the absence of PARP activity, accumulating
SSBs lead to DSBs because of replication fork stalling. Whereas
these DSBs are rapidly repaired by HR in normal cells, they can
only be repaired by error-prone mechanisms in BRCA1-deficient
cells, resulting in gross chromosomal rearrangements and cell
death. Indeed, recent clinical trials have demonstrated antitumor
activity of the PARP inhibitor olaparib in BRCA1-associated
cancer with only few side-effects (Fong et al., 2009, 2010; Tutt
et al., 2010).
BRCA1 is a large nuclear protein that contains an N-terminal
RING domain required for heterodimerization of BRCA1 with
BARD1. The BRCA1/BARD1 heterodimer has E3 ubiquitin ligase
activity with the class of UbcH5 E2 ubiquitin conjugating
enzymes (Mallery et al., 2002; Xia et al., 2003). BRCA1/
BARD1-dependent ubiquitin conjugates occur at sites of DNA
DSBs suggesting that the BRCA1/BARD1 heterodimer is impor-
tant for DNA repair and thereby for the tumor suppressive func-
tion of BRCA1 (Morris and Solomon, 2004). Heterodimerization
of BRCA1 and BARD1 is also important for their stability in vivo
(Hashizume et al., 2001; Joukov et al., 2001) and their nuclear
localization (Fabbro et al., 2002).
The BRCA1/BARD1 heterodimer appears to be important for
the tumor suppressor activity of BRCA1, because mammary-
specific inactivation of either BRCA1 or BARD1 in mice induces
mammary tumors with similar kinetics and histological features
(Shakya et al., 2008). Several germline mutations within the
RING finger domain of BRCA1 have been linked to develop-
ment of breast and ovarian cancers (Castilla et al., 1994; Fried-
man et al., 1994). The C61G mutation in the BRCA1 RING
domain is one of the most frequently reported missense vari-
ants (BIC database; http://research.nhgri.nih.gov/bic/) and
reduces the binding between BRCA1 and BARD1. This muta-
tion also disrupts the interaction of BRCA1 with E2 ubiquitin
conjugating enzymes and thereby abrogates the E3 ubiquitin
ligase activity of the BRCA1/BARD1 heterodimer (Hashizume
et al., 2001; Mallery et al., 2002; Ruffner et al., 2001).
In this study we set out to investigate the importance of the
RING domain for the various in vivo functions of BRCA1 and its
potential importance in therapy response.
RESULTS
Embryonic Lethality of Brca1C61G Mutant Mice
To analyze the physiological role of the BRCA1 RING domain in
mammalian cells, we generated Brca1C61G knock-in mice
carrying a substitution of a conserved RING cysteine (Cys;
TGT) into a glycine (Gly; GGT) at amino acid position 61 (Figure 1).
This enabled us to exactly reproduce the human BRCA1C61G
mutation in the mouse Brca1 gene.
To determine the effects of Brca1C61G expression on normal
mouse development, we investigated whether homozygous
Brca1C61G mice were viable. Intercrossing of heterozygous
Brca1C61G mice did not yield Brca1C61G homozygous pups
(Table S1 available online), indicating that the Brca1C61G muta-
tion leads to embryonic lethality due to loss of BRCA1 RING
function. To study at which stage of development homozygous
Brca1C61G mice die, embryos were harvested at several time798 Cancer Cell 20, 797–809, December 13, 2011 ª2011 Elsevier Incpoints after gestation and genotyped. Although homozygous
Brca1C61G embryos were still recovered at Mendelian ratios
at embryonic day (E) 10.5 (Table S1), they were already
severely delayed in development at E9.5 compared to
Brca1C61G/+ and Brca1+/+ embryos (Figure 1E). From E12.5
on, Brca1C61G/C61G embryos could no longer be detected
(Table S1). In line with this, BRCA1-deficient mouse embryonic
stem (ES) cells expressing human BRCA1-C61G showed a
proliferation defect, which was independent of p53 status and
not caused by reduced expression levels of BRCA1-C61G
protein (Figure S1).
Mammary Tumor Development
in K14cre;Brca1F/C61G;p53F/F Mice
To study the role of BRCA1 RING function in tumor suppression,
we introduced the Brca1C61G allele into the K14cre;Brca1F/F;
p53F/F (KB1P) mouse mammary tumor model, in which Cre re-
combinase-mediated deletion of Brca1F and p53F alleles is
induced in several epithelial tissues including skin andmammary
gland epithelium (Liu et al., 2007). Brca1C61Gmice were crossed
with KB1P mice to generate cohorts of K14cre;Brca1F/C61G;
p53F/F (KB1C61GP) mice and KB1P control littermates, which
were monitored for spontaneous tumor formation. Whereas
KB1P mice showed a median tumor-free survival of 236 days,
KB1C61GP mice developed tumors with a significantly shorter
median latency of 197 days (Figure 2A; log rank test p =
0.0003). However, when we scored for mammary tumors only,
no significant difference in tumor-free survivalwasobserved (Fig-
ure 2B; log rank test p = 0.5657). When only skin tumors were
taken into account, median tumor-free survival of KB1C61GP
animals was again significantly reduced compared to KB1P
mice (Figure S2; log rank test p = 0.0117), showing that the differ-
ence in median tumor-free survival between KB1C61GP and
KB1P mice is mainly due to skin tumors rather than mammary
tumors. Although the frequencyofmammary tumorswascompa-
rable for KB1C61GP and KB1Pmice (63% versus 59%, respec-
tively, the incidence of skin tumors was markedly lower in
KB1C61GP mice than in KB1P mice (47% versus 75%; Fig-
ure 2C). Consequently, KB1P mice more often carried both
mammary and skin tumors (37%) than KB1C61GP mice (13%).
Characterization of K14cre;Brca1F/C61G;p53F/F
Mammary Tumors
On the basis of their histomorphological characteristics, the
majority of mammary tumors that developed in both KB1P
(89%) and KB1C61GP animals (87%) were classified as poorly
differentiated solid carcinomas (Figure S3). In both groups only
a small percentage of tumors were classified as carcinosar-
comas, characterized by the presence of spindle-shaped cells
(KB1C61GP: 2%; KB1P: 7%; Figure S3). Other tumors that
developed in KB1C61GP and KB1P mice were grouped as
lumen-forming carcinomas with varying degrees of glandular
differentiation (Figure S3). Similar to human BRCA1-associated
breast cancer (Lakhani et al., 2002), most KB1C61GP and
KB1Pmammary tumors stained (partly) positive for cytokeratin 8
and negative for vimentin, ER and PR (Figure 3A; Table S2).
Human BRCA1-associated breast tumors are known to
display a high degree of genomic instability (Tirkkonen et al.,
1997) and also mouse KB1P tumors have a considerably higher.
Figure 1. Embryonic Lethality of Brca1C61G
Mutant Mice
(A) Schematic overview of the Brca1wt and
Brca1C61G allele before and after Cre-mediated
excision of the neomycin (neo) selection marker.
The Brca1C61G mutation is indicated with an
asterisk. EcoN1 restriction sites are depicted. tk,
thymidine kinase negative selection cassette; Cre,
Cre recombinase; p, Brca1 intron 4 probe.
(B) Mouse Brca1+ and Brca1C61G DNA and protein
sequence. Location of mutation and correspond-
ing change of amino acid residue are indicated.
(C) Southern blot analysis of Brca1C61G/+ (1) and
Brca1+/+ (2) genomic DNA.
(D) Melting curve genotyping of Brca1+/+ (blue),
Brca1C61G/+ (red), andBrca1C61G/C61G (green)mice.
(E) Embryonic lethality of Brca1C61G/C61G mice.
PicturesofBrca1+/+,Brca1C61G/+, andBrca1C61G/C61G
mice at embryonic day 9.5 (E9.5). See also Table
S1 and Figure S1.
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(KP) mice (Holstege et al., 2010; Liu et al., 2007). To investigate
the level of genomic instability in KB1C61GP tumors, we
measured DNA copy number aberrations (CNAs) in mammary
tumors from KB1C61GP (n = 20), littermate KB1P (n = 18) and
KPmice (n = 19) using array comparative genomic hybridization
(aCGH). When applying the comparative module of the R
package KCsmart (de Ronde et al., 2010; Klijn et al., 2008), we
did not find any differences between recurrent CNAs of
KB1C61GP and KB1P tumors (Figure 3B). We also counted the
number of segments per individual tumor as a measure of
genomic instability and aggregated the results of individual
tumors per genotype (Figure 3C). In line with our previous find-Cancer Cell 20, 797–809, Dings, KB1P tumors were found to be
more genomically unstable than KP
tumors (Wilcoxon rank sum test p =
0.04632). KB1C61GP tumors also had
a significantly higher level of genomic
instability than KP tumors (Wilcoxon
rank sum test p = 0.008207), and no
significant differences could be detected
between KB1C61GP and KB1P tumors
(Wilcoxon rank sum test p = 0.4383).
Thus, the histological features and
aCGH profiles of KB1C61GP mammary
tumors are indistinguishable from those
of KB1P control tumors.
Whereas some studies have suggested
that the BRCA1C61G mutation leads to
reduced BRCA1 stability due to disrup-
tion of the BRCA1-BARD1 interaction
(Hashizume et al., 2001; Joukov et al.,
2001), others have found that the muta-
tion has only a slight impact on BRCA1
stability (Brzovic et al., 2001; Nelson and
Holt, 2010). To test the effect of the
Brca1C61G mutation on protein stability,
several KB1C61GP and control tumorswere analyzed for BRCA1 protein expression by western blot
(Figure 3D). KB1C61GP and control KP tumors expressed
BRCA1 protein at similar levels, indicating no significant insta-
bility of the murine BRCA1-C61G protein.
Response of K14cre;Brca1F/C61G;p53F/F Mammary
Tumors to the PARP Inhibitor Olaparib
Mammary tumors arising in the KB1P mouse model can be
transplanted orthotopically into female wild-type mice without
losing their histomorphological features, molecular characteris-
tics, and drug sensitivity profile (Rottenberg et al., 2007, 2010).
We used this transplantation system to study the response of
KB1C61GP mammary tumors to the clinical PARP inhibitorecember 13, 2011 ª2011 Elsevier Inc. 799
Figure 2. Spontaneous Tumor Development in KB1C61GP and KB1P Mice
(A) Tumor-free survival of KB1C61GPmice (K14cre;Brca1F/C61G;p53F/F; blue curve; T50 = 197 days, n = 61 mice) and KB1Pmice (K14cre;Brca1
F/F;p53F/F; green
curve; T50 = 236 days, n = 37 mice). T50: median tumor-free survival; n, number of mice.
(B) Mammary tumor-free survival KB1C61GP (blue; T50 = 196 days, n = 30 mice) and KB1P mice (green; T50 = 225 days, n = 8 mice).
(C) Distribution of different tumor types in KB1C61GP and KB1Pmice. Purple, only one or multiple mammary tumor(s); yellow, only one or multiple skin tumor(s);
orange, both mammary and skin tumor(s); blue, another kind of tumor. See also Figure S2.
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KP tumors were transplanted into the fourth mammary gland of
syngeneic recipient females and tumor-bearing mice were either
treated with olaparib or left untreated (Figure 4A). In all cases,
untreated animals had to be sacrificed within 12 days because
of a large tumor (Figure 4B, left panel; Figure S4). No significant
differences in overall survival (OS) after transplantation could be
observed between KP, KB1C61GP, and KB1P tumors (KP
versus KB1C61GP: log rank test p = 0.1953; KB1C61GP versus
KB1P: log rank test p = 0.1210). Whereas mice carrying KP
tumors did not respond to olaparib treatment (Figures 4B and
4C, red curves; Figure S4), the median survival of mice carrying
KB1P tumors increased from 12 to 60 days following treatment
with olaparib and their tumors disappeared during treatment
(Figures 4B and 4C, green curves; Figure S4). However, as re-
ported before (Rottenberg et al., 2008), KB1P tumors could not
be eradicated with this 28-day dosing schedule and all tumors
grew back after the end of treatment. Interestingly, mice trans-
planted with KB1C61GP tumors had an average OS of 23 days
after start of treatment (Figure 4B, right panel, blue curve), which
was significantly better than KP tumors, but significantly worse
than KB1P tumors (KP versus KB1C61GP: log rank test p =
0.0002, KB1C61GP versus KB1P: log rank test p = 0.006). In
contrast to KB1P tumors, KB1C61GP tumors never shrank in
response to olaparib treatment, but continued to grow after
a short period of tumor stasis (Figure 4C). These data indicate
that, whereasKB1C61GP andKB1P tumors have similar charac-
teristics, their responses to olaparib differ substantially.800 Cancer Cell 20, 797–809, December 13, 2011 ª2011 Elsevier IncResponse of K14cre;Brca1F/C61G;p53F/F Mammary
Tumors to Cisplatin
We also investigated the response of KB1C61GP tumors to the
maximum tolerable dose (MTD) of cisplatin, to which KB1P
tumors never develop complete resistance (Rottenberg et al.,
2007). We again transplanted several individual KB1C61GP,
KB1P, and KP mammary tumors and treated tumor-bearing
mice with cisplatin (Table S3; Figure 5A). Because cisplatin can
have toxic side effects after multiple rounds of treatment, we
studied both OS and tumor-free survival (TFS). Although the
median OS of mice transplanted with KP tumors was prolonged
from 11 to 48 days following cisplatin treatment (Figure 5B, red
curve), they quickly developed resistance (Figure S5A). Conse-
quently, 38% of the mice transplanted with KP tumors had to
be sacrificed because of resistance (Figure 5C). As described
before (Rottenberg et al., 2007), KB1P tumors respond well to
platinum therapy, showing an increase in median OS from
12 days to 196 days following cisplatin treatment (Figure 5B,
green curve). KB1P tumors never developed resistance and ulti-
mately all animals had to be sacrificed because of toxicity (Fig-
ure 5C; Figure S5A). Remarkably, mice transplanted with
KB1C61GP tumors showed a significantly worse OS after
cisplatin therapy than mice transplanted with KB1P tumors (Fig-
ure 5B; Figure S5B; KB1C61GP: T50 = 70 days; KB1P: T50 =
196 days; log rank test p = < 0.0001). This difference in survival
was even more pronounced when only animals that had to be
sacrificed because of a large tumor were scored (Figure S5C;
log rank test p = < 0.0001). Moreover, KB1C61GP tumors readily.
Figure 3. Molecular Characterization of
KB1C61GP Mouse Mammary Carcinomas
(A) Immunohistochemical staining of sections from
a KB1C61GP solid mouse mammary carcinoma
for cytokeratin 8 (CK8), vimentin (Vim), estrogen
receptor (ER), and progesterone receptor (PR).
(B) Comparative KC-Smart profiles of 20
KB1C61GP (blue) and 18 KB1P (green) mouse
mammary carcinomas. Chromosome numbers
are represented on the x axis, KC score (measure
of recurrence and strength of copy number
change over a group of tumors) is depicted on the
y axis.
(C) Level of genomic instability in KB1C61GP
mouse mammary carcinomas. The graph displays
the number of discrete copy number aberrations
identified by segmentation of aCGH profiles from
BRCA1-proficient K14cre;p53F/F (KP) tumors (red
boxplot), KB1C61GP tumors (blue boxplot), and
KB1P tumors (green boxplot). The size of the box
represents the variation between tumors within
a group and the line within the box depicts the
average level of genomic instability. Errors bars
indicate standard deviation (SD).
(D) BRCA1 protein expression in KB1C61GP
mouse mammary carcinomas. Lanes 1–5,
KB1C61GP tumors; lanes 6–8, KB1P littermate
control tumors; lane 9, KP tumor. PolII protein
expression was used as loading control. See also
Figure S3 and Table S2.
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sacrificed because of therapy-refractory tumors (Figure 5C; Fig-
ure S5D; Table S3). In fact, no significant difference in OS after
cisplatin therapy was observed between mice transplanted
with KB1C61GP and KP tumors, respectively (Figure 5B; log
rank test p = 0.5823). Thus, the response of KB1C61GP tumors
to cisplatin treatment is more similar to KP tumors than to KB1P
tumors.
Acquired Cisplatin Resistance in K14cre;
Brca1F/C61G;p53F/F Mammary Tumors
To investigate whether resistance of KB1C61GP tumors to
cisplatin was stable, we retransplanted both platinum-sensitive
and platinum-resistant tumors derived from four different
KB1C61GP donor tumors. There was no significant differenceCancer Cell 20, 797–809, Din tumor outgrowth after retransplanta-
tion between cisplatin-sensitive and
cisplatin-resistant tumors (Figure 5D, left
upper panel; log rank test p = 0.2102).
When tumors reached a volume of
200 mm3, mice were treated with the
MTD of cisplatin. Mice transplanted with
platinum-resistant tumors responded
significantly worse to cisplatin treatment
than animals transplanted with platinum-
sensitive tumors (Figure 5D, right upper
panel; log rank test p = 0.0003), indicating
that cisplatin resistance of KB1C61GP
tumors is a stably acquired trait.To probe whether platinum resistance in KB1C61GP tumors
could be due to a platinum-specific mechanism such as
increased nucleotide excision repair (NER) or to restoration of
HR, we investigated cross-resistance of cisplatin-resistant
KB1C61GP tumors to olaparib. Mice engrafted with cisplatin-
sensitive and cisplatin-resistant KB1C61GP tumors were
treated with 50 mg/kg olaparib for 28 successive days. Mice
carrying platinum-sensitive KB1C61GP tumors showed a good
response to olaparib, which was comparable to the response
to cisplatin (Figure 5D, right upper panel and left lower panel;
cisplatin T50 = 29 days versus olaparib T50 = 32 days). Compared
to mice transplanted with platinum-sensitive tumors, mice with
platinum-resistant tumors responded significantly worse to ola-
parib treatment, showing a median OS of only 10 days (Fig-
ure 5D, left lower panel; log rank test p = 0.0002). Thus,ecember 13, 2011 ª2011 Elsevier Inc. 801
Figure 4. Olaparib Response of KB1C61GP Mammary Tumors
(A) Schematic representation of olaparib treatment schedule. Tx, orthotopic transplantation of fragments from spontaneous mouse mammary tumors; T0, start of
treatment at a tumor volume of 200 mm3 (100%). Mice received a daily dose of 50 mg/kg olaparib intraperitoneally for 28 consecutive days.
(B) Overall survival (OS) curves of mice transplanted withKB1C61GP (blue),KB1P (green), and KP (red) tumors. The left graph depicts untreated animals; the right
graph shows mice treated with olaparib. T50, median OS; n, number of mice. KP without treatment: T50 = 11 days, n = 4 mice, KP with olaparib treatment: T50 =
10 days, n = 5 mice; KB1C61GP without treatment: T50 = 7 days, n = 5 mice, KB1C61GP with olaparib treatment: T50 = 23 days, n = 10 mice; KB1P without
treatment: T50 = 12 days, n = 4 mice, KB1P with olaparib treatment: T50 = 60 days, n = 7 mice.
(C) Comparison of relative mammary tumor volumes during 28-day treatment with olaparib. Tumor volumes are relative to the tumor volume at start of treatment
(day 0, 100% = ±200 mm3). Error bars indicate standard error of the mean (SEM). See also Figure S4.
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to olaparib.
We next investigated cross-resistance of cisplatin-resistant
KB1C61GP tumors to the bifunctional alkylator nimustine.
Bifunctional alkylators may be more lethal to HR-deficient cells
than platinum agents because they are more efficient in inducing
DNA interstrand crosslinks (ICLs), which can only be resolved by
HR-mediated DNA repair (Deans and West, 2011). Treatment of
mice carrying cisplatin-sensitiveKB1C61GP tumorswith a single
dose of 48 mg/kg nimustine resulted in a median OS of 28 days,
which is comparable to the median OS after treatment with
cisplatin (T50 = 29 days) or olaparib (T50 = 32 days; Figure 5D).
Interestingly, a similar median OS was observed following
nimustine treatment of mice carrying cisplatin-resistant
KB1C61GP tumors (T50 = 24 days) and there was no significant802 Cancer Cell 20, 797–809, December 13, 2011 ª2011 Elsevier Incdifference in OS benefit from nimustine treatment between
animals carrying platinum-resistant or platinum-sensitive tumors
(Figure 5D, right lower panel; log rank test p = 0.7458). Thus,
although cisplatin-resistant KB1C61GP tumors show cross-
resistance to PARP inhibition, no cross-resistance to bifunc-
tional alkylators such as nimustine was observed.
No Genetic Reversion of the Brca1C61G Mutation
in Therapy-Resistant Tumors
The cross-resistance of cisplatin-resistant KB1C61GP tumors to
olaparib suggests that the mechanism of platinum resistance
involves adaptation of HR-mediated DNA repair. Because
secondary mutations in BRCA1/2 can lead to resistance to plat-
inum agents and olaparib in BRCA1/2-deficient cell lines and
ovarian tumors (Sakai et al., 2008, 2009; Swisher et al., 2008),.
Figure 5. Cisplatin Response of KB1C61GP
Mammary Tumors
(A) Schematic representation of cisplatin treat-
ment schedule. Tx, orthotopic transplantation of
fragments from spontaneous mouse mammary
tumors. T0, start of treatment at a tumor volume of
200 mm3, corresponding to a relative tumor
volume (RTV) of 100%. T13, if the RTV on day 13
wasR50%,mice received an additional treatment
that was repeated every 2 weeks until their tumor
shrank to a RTV of %50%. If the RTV at T13 was
%50%, retreatment was postponed until the
tumors grew back to their starting volume.
(B) OS curves of mice transplanted with
KB1C61GP (blue), KB1P (green), and KP (red)
tumors after cisplatin treatment.KP, T50 = 48 days,
n = 21 mice; KB1C61GP, T50 = 70 days, n = 32
mice; KB1P, T50 = 196 days, n = 20 mice.
(C) Causes of death of tumor-bearing mice after
treatment with cisplatin. The stacked bars depict
the percentage of mice that are still alive (orange)
or sacrificed because of cisplatin-associated
toxicity (gray) or cisplatin-resistant tumors (blue).
(D) Effects of cisplatin, olaparib, or nimustine on
OS of mice transplanted with cisplatin-sensitive
(blue) and cisplatin-resistant (red) KB1C61GP
tumors. Top left panel: OS of untreated mice
(cisplatin-sensitive: T50 = 8 days, n = 4 mice;
cisplatin-resistant: T50 = 10 days, n = 6 mice). Top
right panel: OS after treatment with a single dose
of 6mg/kg cisplatin (cisplatin-sensitive: T50 =
29 days, n = 8 mice; cisplatin-resistant: T50 =
17 days, n = 8 mice). Bottom left panel: OS after
daily treatment with 50 mg/kg olaparib for 28
consecutive days (cisplatin-sensitive: T50 =
32 days, n = 10 mice; cisplatin-resistant: T50 =
10 days, n = 8 mice). Bottom right panel: OS after
treatmentwith a single dose of 48mg/kg nimustine
(cisplatin-sensitive: T50 = 28 days, n = 7 mice;
cisplatin-resistant: T50 = 24 days, n = 7 mice). See
also Table S3 and Figure S5.
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tumors was due to genetic reversion of the Brca1C61G mutation.
Sanger sequencing and southern blot analysis showed that all
cisplatin-resistant KB1C61GP tumors retained the Brca1C61G
mutation (Figures 6A and 6B; Table S3, and data not shown).
The wild-type band on the southern blot in Figure 6B is probably
derived from wild-type stromal cells from the recipient animal,
since PCR genotyping confirmed complete absence of the
Brca1F allele (data not shown). To exclude other secondary
mutations inBrca1, we sequenced the first eight exons of mouse
Brca1 in all cisplatin-resistant tumors. Besides the Brca1C61G
mutation, no other mutations could be detected in the
cisplatin-resistant tumors (data not shown). In conclusion, we
have found no evidence for genetic reversion of the Brca1C61G
mutation as a mechanism of platinum resistance in KB1C61GP
mouse mammary tumors.Cancer Cell 20, 797–809, DNext, we evaluated potential changes
in Brca1C61G mRNA and protein levels in
cisplatin-resistant KB1C61GP tumors.
To avoid unwanted detection ofBrca1D5-13 mRNA expression, we used primers located in the
deleted part of the Brca1 gene. The level of Brca1C61G mRNA
expression in untreated KB1C61GP tumors was comparable to
the level of Brca1 expression in BRCA1-proficient KP tumors
(Figure 6C; Figure S6A). This corresponds to normal levels of
BRCA1 protein in spontaneous KB1C61GP tumors (Figure 3D)
and in BRCA1-deficient mouse ES cells reconstituted with
human BRCA1-C61G (Figure S1B). On average, cisplatin-resis-
tant KB1C61GP tumors did not show a significantly higher level
of Brca1C61G mRNA expression than untreated KB1C61GP
tumors (Figure 6C; Figure S6B). However, we observed substan-
tial heterogeneity between individual tumors, and some
cisplatin-resistant tumors showed higher BRCA1 mRNA and
protein expression than their untreated counterparts (Figures
6C and 6D; Figures S6A and S6B). We did not find evidence
for a direct correlation between high BRCA1 expression levelsecember 13, 2011 ª2011 Elsevier Inc. 803
Figure 6. No Genetic Reversion in Cisplatin-Resistant KB1C61GP Mammary Tumors
(A) Sanger sequencing of DNA from KB1C61GP tumors shows that the c.181T > G mutation in the Brca1C61G allele is retained in cisplatin-resistant tumors.
(B) Southern blot analysis of DNA from normal spleen (S) and KB1C61GP tumors. D, spontaneous donor tumors; U, untreated transplanted tumors; R, cisplatin-
resistant transplanted tumors. T1, T2, T3, and T4 represent individual spontaneous KB1C61GP donor tumors. Transplanted tumors were grouped according to
the KB1C61GP donor tumor from which they originated.
(C) Brca1 qRT-PCR of untreated and cisplatin-resistant transplanted KB1C61GP tumors. Brca1 mRNA expression was normalized to mRNA expression of
a housekeeping gene (HPRT). Brca1 mRNA expression in a KP mammary tumor was set at 100%. Error bars indicate SD. n, number of tumors.
(D) Western blot analysis of untreated (U) and cisplatin-resistant (R) KB1C61GP tumors. PolII protein expression was used as loading control. See also Figure S6.
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BRCA1-C61G expression for the development of platinum resis-
tance remains unclear.
It was recently shown that BRCA1-deficient breast cancers
show derepression of satellite DNA transcription, which may
contribute to tumorigenesis through induction of genomic insta-
bility (Zhu et al., 2011). Presumably, repression of satellite DNA
transcription may also serve as a mechanism of therapy resis-
tance in BRCA1-deficient cancers. We could, however, not
observe significant differences in satellite repeat expression
between BRCA1-proficient KP tumors, BRCA1-deficient KB1P
tumors andKB1C61GP tumors (Figure S6C). In addition, satellite
repeat expression between cisplatin-sensitive and cisplatin-
resistant tumors was not significantly different (Figure S6C).
Hypomorphic Activity of BRCA1-C61G
The poor initial response to olaparib and normal BRCA1 protein
expression in KB1C61GP tumors prompted us to compare their
intrinsic DNA repair capacity to BRCA1-proficient KP tumors and
BRCA1-deficient KB1P tumors. Several KB1C61GP, KP, and
KB1P tumors were transplanted and treated with cisplatin or ola-
parib when they reached a volume of 200 mm3 (Rottenberg
et al., 2008). Mice were sacrificed 24 hr after they received
a single dose of cisplatin or 2 hr after receiving the last of seven
daily doses of olaparib. Subsequently, the level of apoptosis,
proliferation, and DSBs were evaluated by immunohistochem-
istry for cleaved caspase 3, ki67, and pH2AX, respectively. No804 Cancer Cell 20, 797–809, December 13, 2011 ª2011 Elsevier Incdifference in the level of apoptosis and proliferation could be
observed between KB1C61GP, KP, and KB1P tumors, regard-
less of treatment (data not shown). Also the level of DSBs did
not differ significantly between untreated KB1C61GP, KP, and
KB1P tumors (Figures 7A and 7B). As expected, the number of
DSBs increased considerably after treatment with cisplatin for
all tumor groups (Figures 7A and 7B). In line with the hypersensi-
tivity of BRCA1-deficient KB1P tumors to olaparib (Rottenberg
et al., 2008), the number of pH2AX-positive cells was signifi-
cantly higher in olaparib-treated KB1P tumors than in KP tumors
(Figures 7A and 7B, unpaired t test p = 0.0002). Remarkably, the
level of DSBs after olaparib treatment was significantly lower in
KBC61GP tumors than in KB1P tumors (unpaired t test p =
0.0020), suggesting that the DNA damage response is (partially)
intact in KB1C61GP tumor cells. However, BRCA1-C61G
expression alone may not be sufficient to mediate this response,
since BRCA1-deficient ES cells expressing BRCA1-C61G do
not show functional HR activity and are still sensitive to cisplatin
and olaparib (Figures S7A–S7D).
To evaluate whether the decreased amount of damage-
induced DSBs in KB1C61GP tumors could be due to an altered
DNA damage response in vivo, we assessed the formation of
irradiation-induced RAD51 foci (RAD51 IRIFs) in short-term
tumor cell cultures derived from the different tumor genotypes.
As expected, RAD51 IRIFs were observed in HR-proficient
KP tumor cells but not in HR-deficient KB1P tumor cells (Fig-
ure 7C, upper and lower panel, and 7D; Figure S7E; unpaired.
Figure 7. Hypomorphic Activity of BRCA1-C61G In Vivo
(A) Immunohistochemistry of pH2AX foci inKB1C61GP,KB1P, andKPmammary tumors without treatment or after treatment with olaparib or cisplatin.Mice were
sacrificed 2 hr after the last of seven daily doses of olaparib (50 mg/kg intraperitoneally) or 24 hr after a single dose of cisplatin (6 mg/kg intravenously).
(B) Quantification of pH2AX foci in KB1C61GP (gray), KB1P (orange), and KP (blue) tumors without treatment or after treatment with olaparib or cisplatin. Error
bars indicate SD. n, number of tumors.
(C) Immunofluorescence of RAD51 foci (red) in KB1C61GP,KB1P, and KP tumor cell suspensions with or without g irradiation (10 Gy). Nuclei were visualized with
DAPI (blue).
(D) Quantification of RAD51 foci in KB1C61GP (gray; n = 7), KB1P (orange; n = 9), and KP (blue; n = 5) tumors after g irradiation. Percentages of cells with
>10 RAD51 foci were normalized to tumor cells derived from a KP tumor. Error bars indicate SEM. See also Figure S7.
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HR activity of BRCA1-C61G in vitro (Figures S7A–S7D), we did
observe RAD51 IRIFs in short-term cultures derived from
KB1C61GP tumors (Figure 7C, middle panel; Figure S7E). The
number of cells with RAD51 foci after irradiation was significantly
higher in KB1C61GP cells compared to KB1P cells (Figure 7D;
unpaired t test p = 0.0012). Compared to KP tumor cells,
KB1C61GP cells appeared to have a somewhat lower amount
of RAD51-positive cells after irradiation, but this difference did
not reach statistical significance (Figure 7D; unpaired t test
p = 0.0712).
DISCUSSION
We have studied the importance of BRCA1 RING function in
development, tumor suppression, and therapy response using
a mouse model carrying the Brca1C61G missense mutation,
which impairs BRCA1/BARD1 heterodimerization and ubiquitin
ligase activity. Similar to Brca1 null mutant mice, homozygous
Brca1C61G mutants displayed embryonic lethality and heterozy-
gous Brca1C61G mutant mice with tissue-specific loss of p53
and the second Brca1 allele developed mammary carcinomasCanresembling Brca1 null tumors. These findings indicate
a pronounced loss of function of the mutant BRCA1-C61G
protein. However, in contrast to Brca1 null mammary tumors
from KB1P mice, Brca1C61G tumors from KB1C61GP mice
readily became resistant to cisplatin without undergoing genetic
reversion of the C61G mutation. The acquired resistance of
Brca1C61G tumors to platinum drugs and PARP inhibitors
appears to be caused by residual activity of the mutant
BRCA1-C61G protein resulting in an altered DNA damage
response, as these tumors show reduced levels of pH2AX-posi-
tive DNA damage foci after olaparib treatment and formation of
DNA damage-induced RAD51 foci.
The Role of BRCA1 RING Activity in Mouse Development
and Tumor Suppression
To study the role of BRCA1 in normal development and tumor
suppression, a range of conventional Brca1 knockout mouse
models has been generated carrying mutations in different parts
of the gene (Drost and Jonkers, 2009; Evers and Jonkers, 2006).
Most homozygous Brca1 mouse mutants show embryonic
lethality at mid-gestation, whereas known Brca1 hypomorphic
mutants display a less severe, and in case of the Brca1Dexon11cer Cell 20, 797–809, December 13, 2011 ª2011 Elsevier Inc. 805
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et al., 2001; Xu et al., 2001). In terms of their developmental
phenotype, homozygous Brca1C61G mutant mice resemble
Brca1 null mutants rather than Brca1 hypomorphic mutants
that still express a partly functional BRCA1 protein. In line with
this, Chang et al. (2009) showed that BAC transgenic mice ex-
pressing the Brca1C61G variant failed to rescue the embryonic
lethality of Brca1 knockout mice. Together, these data show
that BRCA1 RING activity is essential for embryonic survival.
BRCA1 RING activity is also essential for tumor suppression,
because KB1C61GP mice developed undifferentiated, ER-
negative mammary carcinomas that closely resembled Brca1
null mammary tumors and human BRCA1-mutated breast
tumors.
The Role of BRCA1 RING Activity in Therapy Response
and Resistance
Although human BRCA1-deficient tumors are very sensitive to
DSB-forming agents, they eventually become resistant.
Secondary mutations in the BRCA1 gene appear to be one
mechanism for ovarian carcinomas to develop platinum resis-
tance (Swisher et al., 2008), suggesting that restoration of
BRCA1 expression is required for resistance to platinum-based
chemotherapy. In line with this, Brca1 null mouse mammary
tumors with a large intragenic deletion of Brca1 exons 5–13 fail
to develop resistance and remain hypersensitive to cisplatin or
carboplatin even after multiple rounds of treatment (Rottenberg
et al., 2007).
We found that Brca1C61G mammary tumors from KB1C61GP
mice respondmuch worse to treatment with olaparib or cisplatin
thanBrca1 null tumors from KB1Pmice. KB1C61GP tumors also
developed cisplatin resistance, which was never observed in
KB1P tumors. Surprisingly, we have found no evidence for
genetic reversion of Brca1 by secondary mutations in cisplatin-
resistant KB1C61GP tumors. The absence of secondary muta-
tions in Brca1 indicates that KB1C61GP tumors may readily
acquire resistance to DNA damaging agents due to residual
activity of the mutant BRCA1-C61G protein. This residual
activity of BRCA1-C61G might relate to another function of
BRCA1 besides HR-mediated DNA repair, such as its reported
role in gene silencing in constitutive heterochromatin (Zhu
et al., 2011). However, we obtained no evidence for restoration
of heterochromatin-mediated silencing in therapy-resistant
KB1C61GP tumors.
It is also possible that more subtle alterations, such as
increased expression of BRCA1-C61G or adaptations in the
DNA damage response network might suffice to trigger resis-
tance to HRD targeted therapy in KB1C61GP tumors. In line
with this, we found that cisplatin-resistant KB1C61GP tumors
were cross-resistant to the clinical PARP inhibitor olaparib,
which induces DSBs through inhibition of SSB repair. This
finding excludes platinum-specific resistance mechanisms
such as increased NER activity (Martin et al., 2008) or reduced
expression of the copper transporter CTR1 (Ishida et al., 2010)
and advocates for adaptation at the level of HR-mediated DNA
repair. Nevertheless, cisplatin-resistant KB1C61GP tumors
were still sensitive to the bifunctional alkylator nimustine. This
might be due to the fact that nimustine causes more ICLs and
may therefore bemore lethal to cells with decreasedHR capacity806 Cancer Cell 20, 797–809, December 13, 2011 ª2011 Elsevier Incthan cisplatin (Deans and West, 2011). Consistent with a role in
ICL repair, BRCA1 has been shown to associate with FANCD2
(Taniguchi et al., 2002), one of the central proteins in the Fanconi
Anemia pathway, and siRNA depletion of BRCA1 results in loss
of damage-induced FANCD2 foci (Vandenberg et al., 2003).
Hypomorphic Activity of BRCA1-C61G
We have obtained evidence that residual activity of the mutant
BRCA1-C61G protein in the DNA damage response underlies
the resistance of KB1C61GP tumors to olaparib and cisplatin.
Compared to BRCA1-deficient tumors, KB1C61GP tumors
showed more DNA damage-induced RAD51 foci and fewer
pH2AX positive cells, suggesting that the DNA repair process
in KB1C61GP tumors is (partially) intact. However, basic HR
levels of both human (Ransburgh et al., 2010) and mouse
C61G mutant cells (Figures S7A and S7B) in vitro are very low.
This apparent discrepancy between in vitro HR reporter activity
and in vivo response of BRCA1-C61G mutant mammary tumors
toDNAdamage could be the result of differences between in vivo
and in vitro assays or of differences in cell type. Alternatively,
additional (epi)genetic alterations might contribute to the altered
DNA damage response of BRCA1-C61G mutant tumors.
Themousemodel we have used to investigate the in vivo func-
tions of the BRCA1 RING domain carries the Brca1C61G
missense mutation, which mutates the first cysteine residue in
the last C-X2-C pair of Zn
2+ binding ligands within the BRCA1
RING domain (Brzovic et al., 2001). The C61G mutation in the
BRCA1 RING domain is one of the most frequently reported
missense variants (BIC database; http://research.nhgri.nih.gov/
bic/) and linked to the development of breast and ovarian cancer
(Castilla et al., 1994; Friedman et al., 1994). This mutation
reduces the binding between BRCA1 and BARD1, and inhibits
E2 conjugating enzyme interaction and thereby the E3 ubiquitin
ligase activity of the heterodimer (Hashizume et al., 2001;Mallery
et al., 2002; Ruffner et al., 2001). It is interesting to compare our
results to data obtained with the synthetic Brca1I26A mutation
(Reid et al., 2008; Shakya et al., 2011), which is suggested to
produce a protein that lacks the E3 ubiquitin ligase activity but
retains the ability to heterodimerize with BARD1 (Brzovic et al.,
2003; Christensen et al., 2007). Cells expressing BRCA1-I26A
are able to repair DSBs by HR at the same level as wild-type cells
(Reid et al., 2008), whereas BRCA-C61Gmutant cells have a very
low HR activity (Figures S7A and S7B) (Ransburgh et al., 2010).
Although mammary tumor development is observed in
KB1C61GP mice expressing BRCA1-C61G, BRCA1-I26A is
able to prevent tumor formation to the same degree as wild-
type BRCA1 (Shakya et al., 2011). This suggests that not the
enzymatic activity but rather another function of the RING
domain (e.g., BRCA1/BARD1 heterodimerization) is essential
for the tumor suppressive activity of BRCA1.
Clinical Implications
We believe that the work presented in this study may have
important diagnostic and therapeutic implications. We show
that secondary mutations in the Brca1 gene are not always
required to develop resistance to platinum drugs or PARP inhib-
itors, as residual activity of BRCA1 mutant proteins with
a dysfunctional RING domain may be sufficient for tumor cells
to withstand treatment with DNA damaging agents..
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resistant tumors in BRCA1C61G mutation carriers may still
respond to treatment with bifunctional alkylators, like nimustine.
This may not only hold true for the BRCA1C61Gmutation but also
for other pathogenic missense mutations in the BRCA1 RING
domain. The fact that Brca1D11/D11;p53/ mouse mammary
tumors, which only express the BRCA1-D11 isoform, can
acquire resistance to cisplatin (Shafee et al., 2008) suggests
that certain pathogenic missense or splicing mutations outside
the BRCA1 RING domain might also produce BRCA1 species
with residual activity resulting in an altered DNA damage
response. Because it will be difficult to obtain treatment
response and survival data for sufficiently large numbers of
patients carrying specific BRCA1 founder mutations, it will be
useful to evaluate the impact of defined Brca1 mutations on
treatment response and resistance in genetically engineered
mouse models for BRCA1-associated breast and ovarian
cancer. It will also be interesting to evaluate the response of
mouse mammary tumors carrying Bard1mutations to treatment
with DSB-forming agents. Shakya et al. (2008) have shown that
BARD1-deficient mouse mammary tumors are virtually indistin-
guishable from BRCA1-deficient tumors. However, it is unknown
whether BARD1-deficient tumors have a similar response to
DNA damaging agents as BRCA1-deficient tumors.
Currently, it is thought that genomic profiling of tumors may
serve as potential diagnostic tool to stratify patients for HRD tar-
geted therapies (Asakawa et al., 2010; Graeser et al., 2010; Lips
et al., 2011; Vollebergh et al., 2011). However, here we show that
although mouse mammary tumors with different Brca1 muta-
tions have identical genomic profiles, they show marked differ-
ences in their capacity to form DNA damage-induced RAD51
foci and in their responses to HRD targeted therapy. It may there-
fore be useful to stratify patients for HRD targeted therapies not
only by genomic profiling of tumors but also according to func-
tional assays, like RAD51 foci formation assays, and the precise
nature of the underlying BRCA1 mutation.
EXPERIMENTAL PROCEDURES
Generation of the Brca1C61G Mutant Mice
MouseEScellswere targetedwith a construct inwhichBrca1 exon5wasmodi-
fied by site-directed mutagenesis to encode the C61Gmutation (Figure 1). The
neomycin selection cassettewas removed fromcorrectly targeted cells byCre-
excision. The resulting ES cells were injected into C57BL/6J blastocysts to
produce chimeric males, which were mated with C57BL/6J females to
generateBrca1C61G/+mice. Brca1C61G/+mice were bred withK14cre;Brca1F/F;
p53F/F (KB1P) animals (Liu et al., 2007) to generate K14cre;Brca1F/C61G;p53F/F
(KB1C61GP) mice. Full details on the generation of the Brca1C61G allele are
provided in the Supplemental Experimental Procedures.
Orthotopic Transplantations and Drug Interventions
All experiments involving animals comply with local and international regula-
tions and ethical guidelines, and have been authorized by our local animal
experimental committee at the Netherlands Cancer Institute (DEC-NKI). Small
fragments of mammary tumors from K14cre;p53F/F (KP), KB1P, or KB1C61GP
mice were transplanted orthotopically in FVB:129/Ola F1 hybrid female mice
as described previously (Rottenberg et al., 2007). When the tumor volume ex-
ceeded 200 mm3, mice were treated with the MTD of cisplatin, olaparib, and
nimustine (Evers et al., 2010; Rottenberg et al., 2007, 2008). To study resis-
tance, animals received additional doses of cisplatin when tumors grew
back to 200 mm3. Animals were sacrificed when the tumor volume exceeded
1,500 mm3 or when they became ill from drug toxicity.CanRAD51 Foci Formation Assay
Cells from cryopreserved tumors were grown on glass coverslips for 36–48 hr,
g-irradiated with 10 Gy, and fixed 6 hr later in 2% paraformaldehyde. RAD51
immunofluorescence was performed as described previously (Bouwman
et al., 2010). To quantify RAD51 foci in single tumor cells, 150–200 cells per
condition were counted blindly. Cells were scored RAD51-positive if they
had more than ten RAD51-positive dots per nucleus.ACCESSION NUMBERS
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